Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MicroPort Scientific Corp. (MCRPF)
Shanghai, SH, CN
MicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics Devices Business, Cardiac Rhythm Management Business, Endovascular and Peripheral Vascular Devices Business, Neurovascular Devices Business, Surgical Devices Business, Heart Valve Business, Surgical Robot Devices Business, and Others. The Cardiovascular Devices Business segment offers integrated medical solutions for the treatment of coronary artery-related diseases, develops, manufactures, and commercializes coronary stents and related delivery systems, along with balloon catheters, passive accessories and active devices, in fulfilling the overall demands of doctors and patients worldwide. The Orthopedics Devices Business segment is involved in the total solutions for the treatment of orthopedic problems, with an extensive range of orthopedics products that include reconstructive joints, spine and trauma products, and other professional implants and instruments. The Cardiac Rhythm Management Business segment develops, manufactures, and markets of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, and cardiac resynchronization therapy devices. The Endovascular and Peripheral Vascular Devices Business segment focuses on providing integrated disease solutions for aortic and peripheral vascular diseases such as thoracic and abdominal aortic aneurysm, aortic dissection, atherosclerosis, and lower extremity arteriosclerotic occlusion. The Neurovascular Devices Business segment specializes in providing total solutions for the treatment of neurovascular diseases, including hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke, continuously focused on research and development, production and commercialization of neurovascular therapeutic and access devices. The Surgical Devices Business segment provides overall solutions for cardiac surgery and emergency life support. The Heart Valve Business segment includes sale, manufacture, research, and development of heart valve devices. The Surgical Robot Devices Business segment designs, develops, and commercializes innovative surgical robots. The company was founded by Zhao Hua Chang in 1998 and is headquartered in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -27.39% | -27.39% | -15.56% | -17.39% | +22.19% | -36.67% | -85.79% | +120.52% | +140.51% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Specialties: +8.3%-3.8% Q4'25: -4.2% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%+112.7% ★ Q4'25: +125.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-22.7% Q4'25: +2.0% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-5.3% Q4'25: -9.4% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%-2.3% Q4'25: -7.4% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+7.4% Q4'25: +4.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×18.02× Q4'25: 14.73× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 1 EPS Ana. |
Dec 2027 7 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
375.84M
est: 376.49M (-0.2%)
|
389.92M
est: 412.02M (-5.4%)
|
444.19M
est: 434.48M (+2.2%)
|
669.49M
est: 659.86M (+1.5%)
|
793.49M
est: 790.86M (+0.3%)
|
648.73M
est: 804.38M (-19.4%)
|
778.64M
est: 779.49M (-0.1%)
|
840.83M
est: 914.92M (-8.1%)
|
950.73M
est: 990.39M (-4.0%)
|
1.04B
est: 1.07B (-3.1%)
|
996.38M
est: 1.12B (-11.4%)
|
1.18B
1.12B – 1.33B
+5.1% YoY
|
1.36B
1.25B – 1.57B
+14.9% YoY
|
1.61B
1.50B – 1.84B
+18.7% YoY
|
| EBITDA |
42.17M
est: -96.31M (+143.8%)
|
77.16M
est: -105.40M (+173.2%)
|
78.15M
est: -111.14M (+170.3%)
|
95.12M
est: -168.79M (+156.4%)
|
83.01M
est: -202.30M (+141.0%)
|
-106.87M
est: -205.76M (+48.1%)
|
-201.14M
est: -199.40M (-0.9%)
|
-430.26M
est: -234.04M (-83.8%)
|
-382.54M
est: -253.35M (-51.0%)
|
60.16M
est: -218.99M (+127.5%)
|
88.83M
est: -230.47M (+138.5%)
|
-242.14M
-272.82M – -228.69M
-5.1% YoY
|
-278.19M
-322.49M – -256.73M
-14.9% YoY
|
-330.10M
-377.65M – -307.96M
-18.7% YoY
|
| EBIT |
4.56M
est: -143.79M (+103.2%)
|
41.08M
est: -157.36M (+126.1%)
|
43.58M
est: -165.94M (+126.3%)
|
52.74M
est: -252.01M (+120.9%)
|
84.53M
est: -302.04M (+128.0%)
|
-175.62M
est: -307.21M (+42.8%)
|
-275.28M
est: -297.70M (+7.5%)
|
-507.61M
est: -349.43M (-45.3%)
|
-533.78M
est: -378.25M (-41.1%)
|
-100.00M
est: -361.45M (+72.3%)
|
-52.95M
est: -380.40M (+86.1%)
|
-399.66M
-450.30M – -377.47M
-5.1% YoY
|
-459.16M
-532.29M – -423.75M
-14.9% YoY
|
-544.84M
-623.32M – -508.31M
-18.7% YoY
|
| Net Income |
-12.09M
est: 2.60M (-564.3%)
|
14.14M
est: 24.12M (-41.4%)
|
18.82M
est: 51.70M (-63.6%)
|
23.91M
est: 42.67M (-44.0%)
|
29.01M
est: 48.84M (-40.6%)
|
-191.25M
est: 6.13M (-3,221.3%)
|
-276.48M
est: -240.62M (-14.9%)
|
-436.52M
est: -349.78M (-24.8%)
|
-477.63M
est: -364.05M (-31.2%)
|
-214.92M
est: -234.88M (+8.5%)
|
48.59M
est: -44.58M (+209.0%)
|
90.19M
82.33M – 107.08M
+302.3% YoY
|
94.87M
86.60M – 112.64M
+5.2% YoY
|
179.50M
163.86M – 213.11M
+89.2% YoY
|
| SGA |
192.77M
est: 234.75M (-17.9%)
|
192.71M
est: 256.90M (-25.0%)
|
200.89M
est: 270.91M (-25.8%)
|
313.53M
est: 411.44M (-23.8%)
|
394.61M
est: 493.12M (-20.0%)
|
438.62M
est: 501.55M (-12.5%)
|
560.49M
est: 486.03M (+15.3%)
|
575.76M
est: 570.48M (+0.9%)
|
540.73M
est: 617.53M (-12.4%)
|
484.68M
est: 621.39M (-22.0%)
|
465.65M
est: 653.98M (-28.8%)
|
687.09M
648.93M – 774.13M
+5.1% YoY
|
789.37M
728.49M – 915.09M
+14.9% YoY
|
936.66M
873.86M – 1.07B
+18.7% YoY
|
| EPS |
-0.01
est: 0.00 (-698.2%)
|
0.01
est: 0.01 (-24.8%)
|
0.01
est: 0.03 (-53.6%)
|
0.02
est: 0.02 (-34.3%)
|
0.02
est: 0.03 (-35.1%)
|
-0.11
est: 0.00 (-3,388.5%)
|
-0.15
est: -0.13 (-14.2%)
|
-0.24
est: -0.19 (-25.7%)
|
-0.26
est: -0.20 (-30.8%)
|
-0.12
est: -0.12 (-0.5%)
|
0.03
est: -0.02 (+214.2%)
|
0.05
0.04 – 0.05
+302.3% YoY
|
0.05
0.04 – 0.06
+5.2% YoY
|
0.09
0.08 – 0.11
+89.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | B- | 3/5 | 4/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hongbin Sun | Chief Financial Officer | 144.0K | male |
| He Li | Board Secretary & Senior VP of Securities and Legal Affairs | — | female |
| Jie Zhang | Chief Technology Officer | — | — |
| Jonathon W. Chen | Rotating Chief Executive Officer | — | male |
| Junder Chiang | Chief Human Resources Officer | — | male |
| Lei Jiang | Co-Chairperson & Chief Marketing Officer - China Executive Committee | — | male |
| Tianbai Yu | President of MicroPort Orthopedics China & Head of Global Supply Chain of Orthopedics | — | male |
| Yimin Xu | Senior EVice President of Regulatory Affairs & Property Management of MicroPort Sinica Co., Ltd | — | male |
| Yiyun Que | EVice President of Intelligent Manufacturing & Global Supply Chain of MicroPort Sinica Co., Ltd. | — | male |
| Badhri Iyengar | President of MicroPort Orthopedics | — | male |
| Zhaohua Chang | Founder, Chairman & Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MCRPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
